In this conversation, Thane Wetting, CEO of Fibrogen, shares his journey from academia to leading a biotech company focused on innovative treatments for oncology and anemia. He discusses the challenges and opportunities in transitioning from big pharma to a nimble biotech environment, emphasizing the importance of patient-centricity, leadership, and resilience. Thane reflects on the current biotech landscape, the role of the FDA, and the significance of maintaining a clear mission amidst market volatility. He also offers insights into investor relations and the importance of having the right people in the right roles to drive success. Chapters 00:00 The Mission Behind Fibrogen 02:18 Thane Wetting's Career Journey 16:58 Transitioning from Big Pharma to Biotech 21:02 Leadership Transition at Fibrogen 30:22 Understanding Prostate Cancer 33:05 Sustaining Core Values During Change 36:09 Navigating Organizational Change and Virtual Transition 38:33 Innovations in Oncology: ADC and Imaging Agents 42:07 Global Expansion and Commercialization Strategies 45:30 Balancing Scientific Ambition with Commercial Realism 49:21 Navigating a Cautious Capital Environment 51:40 FDA Interactions and Regulatory Responsiveness 53:42 Investor Behavior and Risk Management 56:02 Reflections on Career Lessons and Personal Growth 59:25 Advice for Emerging Leaders in Biotech 01:03:29 Staying True to Purpose in Biotech